Botanix Pharmaceuticals (ASX:BOT) FCF Margin % : -4,903.70% (As of Dec. 2023)

View and export this data going back to 1985. Start your Free Trial

What is Botanix Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Botanix Pharmaceuticals's Free Cash Flow for the six months ended in Dec. 2023 was A$-18.54 Mil. Botanix Pharmaceuticals's Revenue for the six months ended in Dec. 2023 was A$0.38 Mil. Therefore, Botanix Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was -4,903.70%.

As of today, Botanix Pharmaceuticals's current FCF Yield % is -8.11%.

The historical rank and industry rank for Botanix Pharmaceuticals's FCF Margin % or its related term are showing as below:

ASX:BOT' s FCF Margin % Range Over the Past 10 Years
Min: -28839.78 Med: -18570.87 Max: -18570.87
Current: -28839.78

During the past 13 years, the highest FCF Margin % of Botanix Pharmaceuticals was -18570.87%. The lowest was -28839.78%. And the median was -18570.87%.

ASX:BOT's FCF Margin % is ranked worse than
94.97% of 1033 companies
in the Biotechnology industry
Industry Median: -148.24 vs ASX:BOT: -28839.78

Botanix Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Botanix Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Botanix Pharmaceuticals FCF Margin % Chart

Botanix Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

FCF Margin %

Get a 7-Day Free Trial

-18,570.87

Botanix Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-2,794.33	2,907.02	-4,903.70

Competitive Comparison of Botanix Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Botanix Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Botanix Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Botanix Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Botanix Pharmaceuticals's FCF Margin % falls into.

Botanix Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Botanix Pharmaceuticals's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-19.128	/	0.103
	=	-18,570.87 %

Botanix Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-18.536	/	0.378
	=	-4,903.70 %

Botanix Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Botanix Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Botanix Pharmaceuticals (ASX:BOT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Botanix Pharmaceuticals Ltd (ASX:BOT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BXPHF:USA

Address

661 Newcastle Street, D2, LEEDERVILLE, WA, AUS, 6007

Website

https://www.botanixpharma.com

Botanix Pharmaceuticals Ltd is a clinical-stage cannabinoid therapeutics company. The company's focus is the development of safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system - Permetrex for direct skin delivery of active pharmaceuticals in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1308 - Plaque Psoriasis, BTX1204 - Atopic Dermatitis, and BTX 1701 - Mild Acne. The majority of Revenue is Derived from Australia.

Botanix Pharmaceuticals (ASX:BOT) Headlines

No Headlines